High hopes for cannabinoid agonists in the treatment of rheumatic diseases

BMC Musculoskeletal Disorders

Richard Barrett-Jolley³  Ali Mobasheri²  Caroline A Staunton¹ 

[1] Department of Musculoskeletal Biology, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool L69 3GA, United Kingdom;Arthritis Research UK Centre for Sport, Exercise and Osteoarthritis, Arthritis Research UK Pain Centre, Medical Research Council and Arthritis Research UK Centre for Musculoskeletal Ageing Research, University of Nottingham, Queen’s Medical Centre, Nottingham NG7 2UH, UK;The D-BOARD European Consortium for Biomarker Discovery, School of Veterinary Medicine, Faculty of Health and Medical Sciences, University of Surrey, Duke of Kent Building, Guildford, Surrey GU2 7XH, UK

关键词: Rheumatoid Arthritis (RA);    Osteoarthritis (OA);    JW133;    Fibroblast-like synoviocytes (FLS);    Ion channels;    Dorsal root ganglia;    Chronic pain;    Cannabis;    Cannabinoids;   

Others  :  1091152
DOI  :  10.1186/1471-2474-15-410

 received in 2014-10-15, accepted in 2014-11-25,  发布年份 2014

【 摘 要 】

There are two well-characterised isoforms of cannabinoid receptor; CB₁ and CB₂ and of these CB₂ is under active investigation as a potential target for treatment of the chronic pain associated with widespread and intractable joint diseases osteoarthritis and rheumatoid arthritis. The recent report by Fukuda et al (BMC Musculoskelet Disord15:275, 2014) in BMC Musculoskeletal Disorders investigates the efficacy of a selective CB₂ agonist, JW133, in both in vitro and in vivo models of rheumatoid arthritis and provides encouraging data. The report shows that JW133 inhibits expression of the CCL2 cytokine, osteoclastogenesis and reduces histological indicators of joint degeneration. Each of these could potentially contribute to beneficial analgesic effects in a therapeutic context.

【 授权许可】

   
2014 Staunton et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
• [2]Howlett AC: Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 1995, 35:607-634.
• [3]Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Geasley PJ: The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007, 152:1092-1101.
• [4]Console-Bram L, Brailoiu E, Brailoiu GC, Sharir H, Abood ME: Activation of GPR18 by cannabinoid compounds: a tale of biased agonism. Br J Pharmacol 2014, 171:3908-3917.
• [5]Brown AJ: Novel cannabinoid receptors. Br J Pharmacol 2007, 152:567-575.
• [6]Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R, McLean A, McIntosh L, Goodwin G, Walker G, Westwood P, Marrs J, Thomson F, Cowley P, Christopoulos A, Pertwee RG, Ross RA: Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 2005, 68:1484-1495.
• [7]McPartland JM, Duncan M, Di Marzo V, Pertwee R: Are cannabidiol and delta -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol 2014. Epub Ahead of Print doi:10.1111/bph.12944
• [8]Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM: Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998, 83:393-411.
• [9]Stella N: Endocannabinoid signaling in microglial cells. Neuropharmacology 2009, 56(Suppl 1):244-253.
• [10]Nisen PD, Zimmerman KA, Cotter SV, Gilbert F, Alt FW: Enhanced expression of the N-myc gene in Wilms’ tumors. Cancer Res 1986, 46:6217-6222.
• [11]Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, Mackie K, Stella N: Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 2003, 23:1398-1405.
• [12]Bottini N, Firestein GS: Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol 2013, 9:24-33.
• [13]Sutton S, Clutterbuck A, Harris P, Gent T, Freeman S, Foster N, Barrett-Jolley R, Mobasheri A: The contribution of the synovium, synovial derived inflammatory cytokines and neuropeptides to the pathogenesis of osteoarthritis. Vet J 2009, 179:10-24.
• [14]Staunton CA, Lewis R, Barrett-Jolley R: Ion channels and osteoarthritic pain: potential for novel analgesics. Curr Pain Headache Rep 2013, 17:1-9.
• [15]Lee H-R, Park KM, Joung YK, Park KD, Do SH: Platelet-rich plasma loaded hydrogel scaffold enhances chondrogenic differentiation and maturation with up-regulation of CB1 and CB2. J Control Release 2012, 159:332-337.
• [16]Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL, Martin BR: 3-(1′,1′-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 1999, 7:2905-2914.
• [17]Fukuda S, Kohsaka H, Takayasu A, Yokoyama W, Miyabe C, Miyabe Y, Harigai M, Miyasaka N, Nanki T: Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis. BMC Musculoskelet Disord 2014, 15:275. BioMed Central Full Text
• [18]Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, Williams B, Gabriel S, Lassere M, Johns N, Buchbinder R, Woolf A, March L: The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 2014, 73:1316-1322.
• [19]Reginster JY, Khaltaev NG: Introduction and WHO perspective on the global burden of musculoskeletal conditions. Rheumatol 2002, 41(Supp 1):1-2.
• [20]Hoy DG, Smith E, Cross M, Sanchez-Riera L, Blyth FM, Buchbinder R, Woolf AD, Driscoll T, Brooks P, March LM: Reflecting on the global burden of musculoskeletal conditions: lessons learnt from the global burden of disease 2010 study and the next steps forward. Ann Rheum Dis 2014, 1-4. doi:10.1136/annrheumdis-2014-205393
• [21]Scanzello CR, Goldring SR: The role of synovitis in osteoarthritis pathogenesis. Bone 2012, 51:249-257.
• [22]Sellam J, Berenbaum F: The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol 2010, 6:625-635.
• [23]Lefevre S, Knedla A, Tennie C, Kampmann A, Wunrau C, Dinser R, Korb A, Schnaker E-M, Tarner IH, Robbins PD, Evans CH, Stürz H, Steinmeyer J, Gay S, Schölmerich J, Pap T, Müller-Ladner U, Neumann E: Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med 2009, 15:1414-1420.
• [24]Pap T, Muller-Ladner U, Gay RE, Gay S: Fibroblast biology: role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res 2000, 2:361-367. BioMed Central Full Text
• [25]Berenbaum F: Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthr Cart 2013, 21:16-21.
• [26]Mobasheri A: The future of osteoarthritis therapeutics: emerging biological therapy. Cur Rheumatol Rep 2013, 15:1-9.
• [27]Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL, Smith MD, Brown MT: Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010, 363:1521-1531.
• [28]Barrett-Jolley R, Lewis R, Fallman R, Mobasheri A: The emerging chondrocyte channelome. Front Physiol 2010, 1:1-11.
• [29]Gallagher J, Howlin J, McCarthy C, Murphy EP, Bresnihan B, FitzGerald O, Godson C, Brady HR, Martin F: Identification of Naf1/ABIN-1 among TNF-α-induced expressed genes in human synoviocytes using oligonucleotide microarrays. FEBS Lett 2003, 551:8-12.
• [30]Byron CR, Barger AM, Stewart AA, Pondenis HC, Fan TM: In vitro expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in cultured equine articular cells. Am J Vet Res 2010, 71:615-622.
• [31]Hardy RS, Hulso C, Liu Y, Gasparini SJ, Fong-Yee C, Tu J, Stoner S, Stewart PM, Raza K, Cooper MS, Seibel MJ, Zhou H: Characterisation of fibroblast-like synoviocytes from a murine model of joint inflammation. Arthritis Res Ther 2013, 15:R24. BioMed Central Full Text
• [32]Zychowska M, Rojewska E, Kreiner G, Nalepa I, Przewlocka B, Mika J: Minocycline influences the anti-inflammatory interleukins and enhances the effectiveness of morphine under mice diabetic neuropathy. J Neuroimmunol 2013, 262:35-45.
• [33]Alvarez P, Levine JD: Screening the role of pronociceptive molecules in a rodent model of endometriosis pain. J Pain 2014, 15:726-733.
• [34]Moore BA, Aznavoorian S, Engler JA, Windsor LJ: Induction of collagenase-3 (MMP-13) in rheumatoid arthritis synovial fibroblasts. Biochim Biophys Acta 2000, 1502:307-318.
• [35]Cagnard N, Letourneur F, Essabbani A, Devauchelle V, Mistou S, Rapinat A, Decraene C, Fournier C, Chiocchia G: Interleukin-32, CCL2, PF4F1 and GFD10 are the only cytokine/chemokine genes differentially expressed by in vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes. Eur Cytokine Netw 2005, 16:289-292.
• [36]Tat SK, Pelletier JP, Velasco CR, Padrines M, Martel-Pelletier J: New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target? Keio J Med 2009, 58:29-40.
• [37]Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, Mechoulam R, Zimmer A, Bab I: Peripheral cannabinoid receptor, CB2, regulates bone mass. PNAS 2006, 103:696-701.
• [38]Burston JJ, Sagar DR, Shao P, Bai M, King E, Brailsford L, Turner JM, Hathway GJ, Bennett AJ, Walsh DA, Kendall DA, Lichtman A, Chapman V: Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint. PLoS One 2013, 8:e80440.
• [39]De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S, Stott CG, Di Marzo V: Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011, 163:1479-1494.